Apar Kishor Ganti, MD, on NSCLC: Real-World Adherence and Persistence of ALK Inhibitors

April 14, 2020 By The ASCO Post Staff

Apar Kishor Ganti, MD, of the University of Nebraska Medical Center, discusses his study findings, which show that alectinib was associated with longer treatment persistence and comparable adherence to other ALK inhibitors (Abstract HSR20-084).

Related Content